Loading cancer entity…
Loading cancer entity…
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03930771 | Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas(TMZ-Cap) | terminated | Phase 2 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02749227 | Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors(PASSILCORT) | terminated | Phase 2 | 4 | Columbia UniversityOTHER | 1 | Apr 27, 2021 |
| clinicaltrials |
| NCT00929669 | Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas(LAR) | terminated | Phase 2 | 2 | University of PennsylvaniaOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00958841 | Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin | terminated | Phase 2 | 118 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 26, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 9, 2022source: clinicaltrials